文献速递心境障碍

20年来精神科医生门诊治疗双相障碍的药物趋势

20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings.
PubMed 文献 · Am J Psychiatry · 2020-04-21

该研究利用1997-2016年美国全国门诊医疗调查数据,分析精神科医生门诊双相障碍访视中药物处方趋势。结果显示抗精神病药使用从12.4%升至51.4%,心境稳定剂从62.3%降至26.4%,抗抑郁药单用(无心境稳定剂)从17.9%升至40.9%。

要点

  • 第二代抗精神病药大幅取代传统心境稳定剂。
  • 抗抑郁药处方持续存在,且无心境稳定剂联用的情况显著增加。
  • 需研究新型抗精神病药与传统心境稳定剂的真实世界疗效与耐受性。

核心结论

  • 过去20年双相障碍门诊药物治疗发生显著变化,第二代抗精神病药在很大程度上取代了传统心境稳定剂。
  • 抗抑郁药处方持续存在,尽管缺乏其治疗双相障碍有效的证据且担忧增加躁狂风险。

研究设计与样本

  • 使用1997-2016年美国全国门诊医疗调查(NAMCS)具有全国代表性的数据。
  • 纳入双相障碍列为主要诊断之一的精神科医生门诊访视。
  • 采用逻辑回归模型识别统计学显著趋势,协变量包括年龄、性别、种族/民族和主要保险类型。

主要发现

  • 抗精神病药处方从1997-2000年的12.4%增至2013-2016年的51.4%(调整OR=5.05,95%CI=3.65-7.01)。
  • 心境稳定剂处方从1997-2000年的62.3%降至2013-2016年的26.4%(调整OR=0.18,95%CI=0.13-0.27)。
  • 抗抑郁药处方在1997-2000年为47.0%,2013-2016年为57.5%。
  • 无心境稳定剂联用的抗抑郁药处方从1997-2000年的17.9%增至2013-2016年的40.9%(调整OR=2.88,95%CI=2.06-4.03)。

临床怎么用

  • 临床需关注抗精神病药在双相障碍门诊治疗中的广泛使用及其长期耐受性。
  • 对单用抗抑郁药治疗双相障碍应保持警惕,因其缺乏疗效证据且可能增加躁狂风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pharmacological options for treating bipolar disorder have increased over the past 20 years, with several second-generation antipsychotics receiving regulatory approval in the 1990s. The authors describe trends in use of pharmacological agents in the outpatient management of bipolar disorder. METHODS: Using nationally representative data from the 1997-2016 National Ambulatory Medical Care Surveys, the authors examined trends in the use of mood stabilizers, first- and second-generation antipsychotics, and antidepressants among psychiatrist visits for which bipolar disorder was listed among the primary diagnoses. A logistic regression model was used to identify statistically significant trends, with covariates including age, gender, race/ethnicity, and primary insurance. RESULTS: Antipsychotics were increasingly more commonly prescribed, increasing from 12.4% of outpatient visits for bipolar disorder in the 1997-2000 period to 51.4% in the 2013-2016 period (adjusted odds ratio=5.05, 95% CI=3.65-7.01). Use of mood stabilizers decreased from 62.3% of visits for bipolar disorder in the 1997-2000 period to 26.4% in the 2013-2016 period (adjusted odds ratio=0.18, 95% CI=0.13-0.27). Prescription of antidepressants occurred in 47.0% of visits for bipolar disorder in the 1997-2000 period and 57.5% in the 2013-2016 period. Prescription of an antidepressant without a mood stabilizer increased substantially, from 17.9% in the 1997-2000 period to 40.9% in the 2013-2016 period (adjusted odds ratio=2.88, 95% CI=2.06-4.03). CONCLUSIONS: Substantial changes have occurred in the treatment of bipolar disorder over the past 20 years, with second-generation antipsychotics in large measure supplanting traditional mood stabilizers. Antidepressant prescriptions persisted despite a lack of evidence for their efficacy in bipolar disorder and concerns about increasing the risk of mania. Research is needed to compare the real-world effectiveness and tolerability of newer antipsychotics with those of traditional mood stabilizers.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rhee TG, Olfson M, Nierenberg AA, et al. 20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings. Am J Psychiatry. 2020. PMID: 32312111. doi:10.1176/appi.ajp.2020.19091000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。